Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IceCure Medical (ICCM) Common Equity (2020 - 2026)

IceCure Medical has reported Common Equity over the past 7 years, most recently at $8.5 million for Q1 2026.

  • For Q1 2026, Common Equity changed N/A year-over-year to $8.5 million; the TTM value through Mar 2026 reached $8.5 million, changed N/A, while the annual FY2025 figure was $9.1 million, 31.15% up from the prior year.
  • Common Equity was $8.5 million for Q1 2026 at IceCure Medical, down from $9.1 million in the prior quarter.
  • Across five years, Common Equity topped out at $25.4 million in Q4 2022 and bottomed at $6.9 million in Q4 2024.
  • The 5-year median for Common Equity is $9.1 million (2025), against an average of $12.4 million.
  • Year-over-year, Common Equity crashed 52.16% in 2023 and then surged 31.15% in 2025.
  • Over 5 years, Common Equity stood at $25.4 million in 2022, then tumbled by 52.16% to $12.2 million in 2023, then tumbled by 43.26% to $6.9 million in 2024, then surged by 31.15% to $9.1 million in 2025, then decreased by 6.15% to $8.5 million in 2026.
  • The last three reported values for Common Equity were $8.5 million (Q1 2026), $9.1 million (Q4 2025), and $6.9 million (Q4 2024) per Business Quant data.